Cue Biopharma (CUE) Operating Leases (2019 - 2025)
Cue Biopharma (CUE) posted Operating Leases of $2.3 million for Q4 2025, down 14.83% sequentially from $2.7 million in Q3 2025, and up 127.92% YoY from $1.0 million in Q4 2024.
Cue Biopharma (CUE) Operating Leases (2019 - 2025) Analysis & Trends
Cue Biopharma has reported Operating Leases for 7 years, with the latest figure at $2.3 million in Q4 2025.
- Quarterly Operating Leases rose 127.92% year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (up 127.92% YoY) and the FY2025 annual result came in at $2.3 million, up 127.92% from the prior year.
- Operating Leases eased to $2.3 million in Q4 2025 per CUE's latest filing, from $2.7 million in the prior quarter.
- Over five years, Operating Leases peaked at $6.8 million in Q2 2022 and troughed at $176000.0 in Q1 2025.
- A 5-year average of $3.0 million and a median of $2.9 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2022 and 2023: Operating Leases plunged 94.91% in 2022, then surged 1113.35% in 2023.
- Over 5 years, Operating Leases stood at $5.1 million in 2021, then slumped by 94.91% to $260600.0 in 2022, then soared by 1113.35% to $3.2 million in 2023, then slumped by 68.28% to $1.0 million in 2024, then jumped by 127.92% to $2.3 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $2.3 million, $2.7 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.29 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 3.10 Mn |
| Mar 31, 2025 | 176,000.00 |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Mar 31, 2024 | 2.58 Mn |
| Dec 31, 2023 | 3.16 Mn |
| Sep 30, 2023 | 3.86 Mn |
| Jun 30, 2023 | 4.60 Mn |
| Mar 31, 2023 | 3.16 Mn |
| Dec 31, 2022 | 260,600.00 |
| Sep 30, 2022 | 6.32 Mn |
| Jun 30, 2022 | 6.76 Mn |
| Mar 31, 2022 | 4.76 Mn |
| Dec 31, 2021 | 5.12 Mn |
| Mar 31, 2021 | 1.09 Mn |
| Dec 31, 2020 | 2.37 Mn |
| Sep 30, 2020 | 3.63 Mn |